Each and every week, we scour the internet to find the best deals available. To do so, we often find ourselves scrolling ...

Aroa Biosurgery’s Myriad product family was a star performer of the company’s first profit since listing in 2020 and is ...

We believe Myriad Genetics’ balance sheet remains decent. At the end of 2023, the company held more than $140 million in cash and marketable securities compared with $39 million in long-term debt.

In addition to further validating the use of Myriad products in these challenging lower extremity reconstructions [2], the study highlights the potential for significant cost benefits.

Special Report: Aroa Biosurgery is targeting the growing lower-limb surgical salvage market with its Myriad family of products, which have been a strong performer for the company and can be used ...